Interní Med. 2017; 19(5): 251-257 | DOI: 10.36290/int.2017.041

Management of osteoarthritis – conservative treatment

MUDr. Eduard ©»astný, Ph.D., prof. MUDr. Tomáą Trč, CSc., MBA, MUDr. Theodoros Philippou
Klinika dětské a dospělé ortopedie a traumatologie 2. lékařské fakulty Univerzity Karlovy v Praze
a Fakultní nemocnice v Motole, Praha

Treatment of osteoarthritis should always be comprehensive and based on a thorough clinical examination of the affected jointwith X-ray evidence of arthrotic changes. The authors in the review article describe the possibilities of conservative treatmentof hyaline cartilage diseases. Its main goal is to slow the progress of the pathological process, reduce pain, reduce joint stiffness,prevent deformity and this improve the quality of life of the patient.

Keywords: osteoarthritis, conservative treatment, non-steroidal anti-inflammatory drugs, hyaluronic acid, SYSADOA

Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©»astný E, Trč T, Philippou T. Management of osteoarthritis – conservative treatment. Interní Med. 2017;19(5):251-257. doi: 10.36290/int.2017.041.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pelletier JP, Martel-Pelletier J. Therapeutic targets in osteoarthritis: from today to tomorrow with new imaging technology. Ann Rheum Dis 2003; Suppl 62: 79-82. Go to original source...
    2. Pelletier JP, Dibattista JA, Roughley P, Mccollum R, Martel-Pelletier J. Cytokines and inflammation in cartilage degradation. Rheum Dis Clin North Am 1993; 19: 545-568. Go to original source... Go to PubMed...
    3. Bellamy N, Kirwan J, Boers M. Recommendations for a core set of outcome measures for phase III clinical trilas in knee, hip and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 1997; 24: 799-802. Go to PubMed...
    4. Lequesne M, Brand K, Bellamy N. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol 1994; Suppl. 41: 65-71. Go to PubMed...
    5. Reginster JY, Deroisy R, Rovati LS, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled trial. Lancet 2001; 357: 251-256. Go to original source... Go to PubMed...
    6. Pavelka K, Gatterová J, Olejárová M, et al. Glucosamine sulphate use and delay of progression of knee OA: 3 years, randomised, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113-2123. Go to original source...
    7. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee OA: report of ESCISIT. Ann Rheum Dis. 2003; 62: 1145-1155. Go to original source...
    8. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006; 354: 795-808. Go to original source... Go to PubMed...
    9. Dougados M, Nguyen M, Berdah L. Evaluation of structure modifying effects of diacerein in hip osteoarthritis: A three year placebo controlled trial. Arthritis Rheum 2001; 44: 2539-2547. Go to original source...
    10. Appelboom T, Schuermans J, Verbruggen G, et al. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand J Rheumatol 2001; 30: 242-247. Go to original source...
    11. Bellamy N,Campbell J,Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006; April 19th: CD005321. Go to original source... Go to PubMed...
    12. Pavelka K, Bečvář R, Böhmová J, et al. Dvojitě slepá, randomizovaná, placebem kontrolovaná, multicentrická studie ověřující účinky přípravků Geladrink Forte u pacientů s osteoartrózou kolena. Ortopedie 2008, 1: 2-7.
    13. Vane LR. Inhibition of prostaglandin synthesis as a mechanismof action for the apirin-like drugs. Nature 1971; 231: 232-235. Go to original source...
    14. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1828. Go to original source... Go to PubMed...
    15. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82: 1153-1158.
    16. Chang KV, Hung CY, Aliwarga F, et al. Comparative effectiveness of platelet-rich plasma injectioms for treating knee joint cartilage degenerative pathology: a systematic review and meta-analysis. Arch Phys Med Rehabil 2014; 95: 562-575. Go to original source... Go to PubMed...
    17. Cerza F, Carni S, Carcangiu A, et al. Comparison between hyaluronic acidand platelet-rich plasma, intra-articular infiltration in the treatment of gonarthrosis. Am J Sports Med 2012; 40: 2822-2827. Go to original source... Go to PubMed...
    18. Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem cells 2014; 32: 1254-1266. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.